Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

09/21/2021 | 08:38am EDT

Immutep Limited announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha (“efti” or “IMP321”) in metastatic breast cancer at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021. SITC 2021 is taking place in Washington, US and virtually from 10-14 November. The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation. Interim OS data from the trial was presented in a spotlight presentation at the San Antonio Breast Cancer Symposium in December 2020. Immutep will make the poster available on its website following publication at SITC 2021 and will host a webinar for investors after the conference.


© S&P Capital IQ 2021
All news about IMMUTEP LIMITED
10/13IMMUTEP : Corporate Connect - A Truly Undervalued Company
PU
10/12IMMUTEP : 2021 Annual General Meeting and Key Dates
PU
10/04IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
MT
10/03IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
PU
10/01IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
AQ
09/29IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
MT
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
PU
09/28IMMUTEP : Receives $2.5 Million Tax Incentive from France
MT
09/28IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
PU
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 2,38 M 1,77 M 1,77 M
Net income 2022 -38,7 M -28,9 M -28,9 M
Net cash 2022 82,0 M 61,2 M 61,2 M
P/E ratio 2022 -8,25x
Yield 2022 -
Capitalization 515 M 385 M 384 M
EV / Sales 2022 182x
EV / Sales 2023 23,8x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,61 AUD
Average target price 1,18 AUD
Spread / Average Target 95,0%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
Frédéric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED45.78%385
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455